T. Meyer

发表

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

P. Furet, N. Lydon, P. Traxler, 1997, Journal of medicinal chemistry.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

P. Furet, N. Lydon, P. Traxler, 1996, Journal of medicinal chemistry.

Entry into a New Class of Protein Kinase Inhibitors by Pseudo Ring Design.

P. Furet, M. Lang, T. Meyer, 2008 .

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

T. Meyer, B. Druker, N. Lydon, 1996, Cancer research.

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Jürg Zimmermann, N. Lydon, H. Mett, 1997 .

Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

N. Lydon, P. Traxler, T. Meyer, 1992, Cancer research.

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

N. Lydon, P. Traxler, T. Meyer, 1990, The Journal of biological chemistry.

4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

P. Traxler, H. Mett, E. Buchdunger, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin.

D. Fabbro, C. Bailly, M. Sancelme, 1998, Bioorganic & medicinal chemistry.

Further minor metabolites of staurosporine produced by a Streptomyces longisporoflavus strain.

H. H. Peter, T. Meyer, P. Hug, 1996, The Journal of antibiotics.

Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin.

H. Mett, E. Buchdunger, T. Meyer, 1995, The Journal of antibiotics.

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

N. Lydon, P. Traxler, T. Meyer, 1991, Journal of medicinal chemistry.

Protein kinase C-α inhibitors; structure-activity relationships in bis-indole series

T. Meyer, J. Lown,, J. Zimmermann, 1995 .

Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.

P. Furet, K. Altmann, F. Hofmann, 2003, Bioorganic & medicinal chemistry letters.

[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.

N. Lydon, P. Traxler, H. Mett, 1995, Journal of medicinal chemistry.

Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties.

D. Fabbro, M. Sancelme, T. Meyer, 1996, Journal of medicinal chemistry.

Furo[2,3-d]pyrimidines and oxazolo[5,4-d]pyrimidines as inhibitors of receptor tyrosine kinases (RTK)

G. Bold, T. Meyer, P. Traxler, 2004 .

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

D. Fabbro, G. Martiny-Baron, J. Brueggen, 2004, Cancer cell.

Phenylamino‐Pyrimidine (PAP)‐Derivatives: A New Class of Potent and Highly Selective PDGF‐Receptor Autophosphorylation Inhibitors.

N. Lydon, H. Mett, E. Buchdunger, 1996 .

Effect of Phenylpyrroles on Glycerol Accumulation and Protein Kinase Activity of Neurospora crassa

T. Meyer, C. Pillonel, 1997 .

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer research.

Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

N. Lydon, H. Mett, E. Buchdunger, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

Peter Traxler, N. Lydon, H. Mett, 1996 .

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

P. Furet, P. Imbach, H. Mett, 1999, Bioorganic & medicinal chemistry letters.

Design, synthesis and investigation of mechanisms of action of novel protein kinase C inhibitors: perylenequinonoid pigments.

T. Meyer, J. Lown,, J. Zimmermann, 1994, Biochemical pharmacology.

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.

J. Mestan, C. Schnell, J. Wood, 2004, Biochimica et biophysica acta.

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.

J. Mestan, P. Furet, T. Meyer, 2004, Bioorganic & medicinal chemistry letters.

Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives.

Jürg Zimmermann, N. Lydon, H. Mett, 1997 .

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

N. Lydon, H. Mett, P. Furet, 1994, Journal of medicinal chemistry.

4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

N. Lydon, P. Traxler, H. Mett, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.

Pascal Furet, Guido Bold, P. Furet, 2006, Journal of medicinal chemistry.

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

J. Mestan, C. Schnell, J. Wood, 2002, Journal of medicinal chemistry.

Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C

Doriano Fabbro, Andreas Fredenhagen, Giorgio Caravatti, 1994 .

Entry into a new class of protein kinase inhibitors by pseudo ring design.

P. Furet, M. Lang, T. Meyer, 2008, Bioorganic & medicinal chemistry letters.

Structure-based design of potent CDK1 inhibitors derived from olomoucine

Thomas Meyer, Hans-Georg Capraro, Pascal Furet, 2000, J. Comput. Aided Mol. Des..

Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.

D. Fabbro, C. Bailly, M. Sancelme, 1997, Journal of medicinal chemistry.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

N. Lydon, P. Traxler, H. Mett, 1997, Journal de pharmacie de Belgique.

Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching

Thomas Meyer, Pascal Furet, Peer R. E. Mittl, 2001, J. Comput. Aided Mol. Des..

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.

P. Furet, G. Bold, T. Meyer, 2004, European journal of medicinal chemistry.

Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo

W. Yung, T. Liu, T. Lafortune, 2007, Molecular Cancer Therapeutics.

Production of anti-(ADP-ribose) antibodies with the aid of a dinucleotide-pyrophosphatase-resistant hapten and their application for the detection of mono(ADP-ribosyl)ated polypeptides.

T. Meyer, T. Meyer, H. Hilz, 1986, European journal of biochemistry.

New Scoring Functions for Virtual Screening from Molecular Dynamics Simulations with a Quantum‐Refined Force‐Field (QRFF‐MD). Application to Cyclin‐Dependent Kinase 2.

Alessandro Curioni, Eric Vangrevelinghe, Tiziana Mordasini, 2006 .

Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src.

E. Altmann, M. Šuša, J. Green, 2000, Bioorganic & medicinal chemistry letters.